Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance
Immune checkpoint blockade has changed the therapeutic landscape of cervical cancer, but clinical benefit remains heterogeneous and difficult to predict with single biomarkers. Cervical cancer is a particularly suitable setting for immune-cell profilin…